E-Mail
IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more
Credit: City of Hope
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in
Cancer API Market Next Big Thing: Major Giants Exelixis, Pfizer, AstraZeneca, Eisai
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, ladies and gentlemen and welcome to the Exelixis Fourth Quarter and Full Year 2020 Financial Results Conference Call. My name is, Latif, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan T. Hubbard
Executive Vice President, Public Affairs and Investor Relations
Thank you, Latif, and thank you all for joining us for the Exelixis fourth quarter and full year 2020 financial results conference call. Joining me on today s call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Gisela Schwab, our Chief Medical Officer; and P.J. Haley, our Executive Vice President of Commercial, who will together review our corporate, financial development and commercial progress for the fourth quarter 2020 ended December 31,
Search jobs 09-Feb-2021 Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology s 2021 Genitourinary Cancers Symposium
- Online event will be accessible at www.exelixis.com -
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium (ASCO GU 2021). The online-only event will be held on Saturday, February 13, 2021, beginning at 5:30 p.m. EST / 2:30 p.m. PST.
During the briefing, Exelixis management and invited guests from the clinical community will discuss and provide context for cabozantinib clinical data presented at ASCO GU 2021, including updated results with extended follow-up data from CheckMate -9ER, the phase 3 pivotal trial evaluating CABOMETYX
The FDA approved an expansion in the label for
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and
Sanofi SA s (NASDAQ: SNY) immunotherapy Libtayo for treating patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor, HHI, or for whom an HHI is not appropriate.
Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.
Moderna Strikes Vaccine Supply Agreements With Taiwan and Columbia
Moderna Inc (NASDAQ: MRNA) announced two supply agreements for its COVID-19 Vaccine - one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses. Under the terms of the agreements, deliveries would begin in mid-2021.
vimarsana © 2020. All Rights Reserved.